Gene Therapy for Leukemia and Lymphoma
ABSTRACT With the advancement of knowledge in immunology and virology, technological improvement in the transduction efficiency of
existing viral vectors, and the development of new viral vectors in the past two decades, gene therapy targeting diseases
at a molecular level has emerged as an exciting and promising strategy for treating hematolymphoid malignancies. Gene therapy
is aimed to correct disease processes by introducing a functional gene into target cells to restore or modify cellular functions.
Unlike conventional therapies for treating cancers, gene therapy, in theory, could deliver precise, malignancy-specific treatment
with minimal side effects on normal cells and biological processes. For many patients with hematolymphoid malignancies who
cannot benefit from the therapies available today, gene therapy may hold the promise of future treatment.